About CLINUVEL

Wednesday, 19 December 2012 17:52

Nomura update "Statistically significant results - will progress to a Phase IIb"

CUV announced successful, statistically significant results from its US Phase IIa pilot study (CUV102) of its afamelanotide 16mg implant in the pigmentation disorder Vitiligo.